Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Change in Receivables (2020 - 2025)

Historic Change in Receivables for Treace Medical Concepts (TMCI) over the last 6 years, with Q3 2025 value amounting to $2.6 million.

  • Treace Medical Concepts' Change in Receivables rose 31167.22% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 40933.75%. This contributed to the annual value of $5.7 million for FY2024, which is 3885.6% down from last year.
  • According to the latest figures from Q3 2025, Treace Medical Concepts' Change in Receivables is $2.6 million, which was up 31167.22% from -$696000.0 recorded in Q2 2025.
  • Treace Medical Concepts' 5-year Change in Receivables high stood at $17.2 million for Q4 2024, and its period low was -$9.3 million during Q1 2025.
  • Moreover, its 5-year median value for Change in Receivables was -$696000.0 (2025), whereas its average is $1.2 million.
  • In the last 5 years, Treace Medical Concepts' Change in Receivables plummeted by 36981.82% in 2021 and then soared by 34348.84% in 2023.
  • Treace Medical Concepts' Change in Receivables (Quarter) stood at $7.0 million in 2021, then soared by 59.14% to $11.1 million in 2022, then rose by 20.95% to $13.4 million in 2023, then increased by 28.09% to $17.2 million in 2024, then tumbled by 85.13% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, -$696000.0 for Q2 2025, and -$9.3 million during Q1 2025.